SCHEMBL2456750

SCHEMBL2456750

COc1ccc(Cn2cc(C(=O)O)ccc2=O)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.53
BRD2 P25440 1/20 0.53
BRD3 Q15059 1/20 0.53
BRDT Q58F21 1/20 0.53
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.52
NPC1 O15118 1/20 0.52
POLB P06746 1/20 0.52
RAB9A P51151 1/20 0.52
CHRM1 P11229 2/20 0.52
ALDH1A1 P00352 2/20 0.50
MAPK10 P53779 1/20 0.50
LMNA P02545 1/20 0.48
ALKBH1 Q13686 1/20 0.48
CMA1 P23946 1/20 0.47
FABP6 P51161 1/20 0.47
PLA2G4B P0C869 1/20 0.47
MMP13 P45452 2/20 0.47
EGLN1 Q9GZT9 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27710864 0.89 CA1 (0.51) BRD4BRD2BRD3BRDTCA1
SCHEMBL2463599 0.87 KDM4E (0.57) BRD4BRD2BRD3BRDTCA1
SCHEMBL14884675 0.84 BRD4 (0.57) BRD4BRD2BRD3BRDTSMN1; SMN2
SCHEMBL1617368 0.82 BRD4 (0.70) BRD4BRD2BRD3BRDTSMN1; SMN2
SCHEMBL5436912 0.81 SDHB (0.47) BRD4BRD2BRD3BRDTNPC1
SCHEMBL2458827 0.81 CMA1 (0.51) CHRM1ALDH1A1LMNACMA1HDAC11
SCHEMBL5437262 0.80 CA1 (0.53) CA1CA2NPC1POLBRAB9A
SCHEMBL7229327 0.79 BRD4 (0.59) BRD4BRD2BRD3BRDTSMN1; SMN2
SCHEMBL5445065 0.79 SDHB (0.54) SMN1; SMN2NPC1RAB9AALDH1A1LMNA
SCHEMBL8276905 0.79 CMA1 (0.53) NPC1POLBRAB9AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791147-B2 Calcium receptor modulating agents AMGEN INC. (US) 2014-07-29 US disclosed
US-20110230517-A1 CALCIUM RECEPTOR MODULATING AGENTS AMGEN INC. 2011-09-22 US disclosed
WO-2010042642-A1 CALCIUM RECEPTOR MODULATING AGENTS AMGEN INC. (US) 2010-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230517-A1 CALCIUM RECEPTOR MODULATING AGENTS CASR, CALCR, CNR1 BRD4 1462/4885BRD2 1789/4885BRD3 2323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.